Back to Journals » OncoTargets and Therapy » Volume 10
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
12,958 | Dovepress* | 12,490+ | 1,207 | 13,697 | |
PubMed Central* | 468 | 233 | 701 | ||
Totals | 12,958 | 1,440 | 14,398 | ||
*Since 27 June 2017 |
View citations on PubMed and Google Scholar